Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | HTR7 | P34969 | 3/20 | 0.45 |
| ▸ | HTR6 | P50406 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | DUT | P33316 | 2/20 | 0.42 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591669 | 0.82 | DRD2 (0.47) | SIGMAR1ALDH1A1KDM4EPOLBTDP1 | |
| SCHEMBL593275 | 0.82 | SIGMAR1 (0.49) | SIGMAR1ALDH1A1KDM4EPOLBTDP1 | |
| SCHEMBL592482 | 0.80 | TSHR (0.50) | SIGMAR1ALDH1A1KDM4EPOLBTDP1 | |
| SCHEMBL592130 | 0.75 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1KDM4EPOLBTDP1 | |
| SCHEMBL5539139 | 0.74 | SIGMAR1 (0.58) | SIGMAR1ALDH1A1KDM4EPOLBTDP1 | |
| SCHEMBL591970 | 0.73 | ALDH1A1 (0.52) | ALDH1A1DRD2DRD3MAPK1 | |
| SCHEMBL5539143 | 0.73 | SIGMAR1 (0.57) | SIGMAR1ALDH1A1KDM4EPOLBTDP1 | |
| SCHEMBL2352106 | 0.73 | DRD2 (0.61) | HTR1AHTR7HTR6DRD2DRD3 | |
| SCHEMBL28156384 | 0.72 | SIGMAR1 (0.67) | SIGMAR1ALDH1A1KDM4EPOLBTDP1 | |
| SCHEMBL14871867 | 0.70 | L3MBTL1 (0.57) | ALDH1A1L3MBTL1MAPTDUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828146-B1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2014-11-05 | — | — | EP | claimed |
| EP-1828146-B1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8114875-B2 | Substituted N-heterocyclic compounds and their use as dopamine D3 receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20090054449-A1 | Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | US | disclosed |
| EP-1828146-A1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066885-A1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054449-A1 | Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands | SLC6A3, DRD3, HTR3A | SIGMAR1 185/4885ALDH1A1 1066/4885KDM4E 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.